Provided by Tiger Trade Technology Pte. Ltd.

Quoin Pharmaceuticals

6.22
+0.10001.63%
Pre-market: 5.75-0.4692-7.54%07:58 EDT
Volume:567.52K
Turnover:3.42M
Market Cap:12.49M
PE:-0.73
High:6.55
Open:5.45
Low:5.43
Close:6.12
52wk High:41.80
52wk Low:3.25
Shares:2.01M
Float Shares:1.36M
Volume Ratio:0.09
T/O Rate:41.74%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.5210
EPS(LYR):-14.7963
ROE:-575.73%
ROA:-114.60%
PB:3.18
PE(LYR):-0.42

Loading ...

NASDAQ Trade Halt Volatility Trading Pause at 09:57 Am

Reuters
·
Jun 24

Quoin Pharmaceuticals Ltd : Maxim Group Cuts Target Price to $16 From $40

THOMSON REUTERS
·
Jun 23

Quoin Pharmaceuticals' Potential Skin Disease Treatment Receives US Name Approval

MT Newswires Live
·
Jun 23

Quoin says FDA conditionally approves QYLEKI as brand name for QRX003 Netherton syndrome drug

Reuters
·
Jun 23

Quoin Pharmaceuticals Completes Establishment Of Japanese Subsidiary To Advance Commercial Readiness For Qrx003

Reuters
·
Jun 18

Quoin Pharmaceuticals establishes Japan subsidiary to support QRX003 commercialization plans

Reuters
·
Jun 18

Quoin reports positive pediatric data in Netherton Syndrome program

TIPRANKS
·
Jun 16

Quoin says QRX003 improves 4 of 6 pediatric Netherton syndrome patients in compassionate use program

Reuters
·
Jun 16

Quoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program

GlobeNewswire
·
Jun 16

Quoin Pharmaceuticals' Skin Disorder Drug Receives Orphan Drug Designation in Japan

MT Newswires Live
·
Jun 04

Quoin says Japan MHLW grants orphan drug status to QRX003 for Netherton syndrome

Reuters
·
Jun 04

Quoin Pharmaceuticals submits QRX003 IND application to FDA

TIPRANKS
·
Jun 02

Quoin Pharmaceuticals submits FDA IND for QRX003 in Peeling Skin Syndrome

Reuters
·
Jun 02

Quoin Pharmaceuticals (QNRX) Receives a Buy from Maxim Group

TIPRANKS
·
May 08

Quoin Pharmaceuticals Q1 EPS $(1.77) Misses $(1.72) Estimate

Benzinga Earnings
·
May 07

Quoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial Results

GlobeNewswire
·
May 07

Quoin Pharmaceuticals Ltd expected to post a loss of $1.93 a share - Earnings Preview

Reuters
·
May 05

Quoin Pharmaceuticals Initiated at Buy by LUCID CAPITAL MARKETS

Dow Jones
·
May 05

Quoin Pharmaceuticals initiated with a Buy at Lucid Capital

TIPRANKS
·
May 04

Quoin Pharma to report Q1 results, provide corporate update May 7

Reuters
·
Apr 30